Last reviewed · How we verify

NCT04699903

Clinical Evaluation of a Point-of-Care (POC), SARS-CoV-2 (COVID-19) IgG Antibody Test in Fingerstick Whole Blood

Completed Last updated 18 June 2021
What this trial tests

trial testing POC SARS-Cov-2 IgG Antibody test in SARS-Cov-2, Covid19 in 201 participants. Completed in 9 April 2021.

Timeline
5 January 2021
Primary endpoint
29 January 2021
9 April 2021

Quick facts

Lead sponsorLumos Diagnostics
StatusCompleted
Study typeOBSERVATIONAL
Enrollment201
Start date5 January 2021
Primary completion29 January 2021
Estimated completion9 April 2021
Sites3 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Lumos Diagnostics

Who can join

1 and older, any sex, with SARS-Cov-2, Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective, multi-center, observational, blinded clinical trial to compare a new point of care (POC) SARS-CoV-2 IgG antibody test to a reference SARS-CoV-2 PCR test using fingerstick whole blood.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Lumos Diagnostics trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04699903.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing